Leadership
Stephen J. McCormack, PhD
CEO & Co-Founder
Veteran biotech operator. Built MannKind ($2B), CytomX ($1.5B), AlleCure (ALK exit), NeuroSystec, Pixium Vision (now Science Corp).
David Cheresh, PhD
Scientific Founder & Advisor
UCSD Pathology Vice Chair. Developed Unituxin (FDA 2015). TargeGen founder (Fedratinib FDA 2019, $7B exit). 26 issued patents.
Sara Weis, PhD
VP of Research & Co-Founder
Drives discovery, translational biology, and the Fibrozumab IND-enabling research roadmap.
Kamal Egodage, PhD
Chief Manufacturing Officer
Leads CMC, biologics process development, scale-up and clinical supply for Fibrozumab.
Doug Frankel
Organizational Development Advisor
Executive Vice President, National Search Associates.
Alfred Atallah, Esq.
Legal Advisor
Heads corporate, IP, and transactional matters supporting financing, patents, and partnerships.
Advisory Board
Michael Karin, PhD
UCSD / NAS member
Tumor inflammation, fibrosis biology.
Andrew Lowy, MD
UCSD Surgical Oncology
Head of Surgical Oncology, PDAC clinical trials.
Bassel El-Rayes, MD
UCSD Health
Deputy Director, Moores Cancer Center.
Dan Von Hoff, MD
Mayo Clinic, Arizona
World renown Pancreas Cancer physician scientist.
David Brenner, MD
Sanford Burnham Prebys CEO
Liver fibrosis & clinical trials.
David Cheresh, PhD
UCSD Research
Scientific founder — angiogenesis, integrins.